cancerimmunolres.aacrjournals.orgHome | Cancer Immunology Research

Skip to main content AACR Publications Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Clinical Cancer Research Molecular Cancer Research Molecular Cancer Therapeutics Register Log in My Cart Advertisement Main menu Home About The Journal AACR Journals Subscriptions Permissions and Reprints Reviewing Articles OnlineFirst Current Issue Past Issues Meeting Abstracts Cancer Immunology Essentials Collections COVID-19 & Cancer Resource Center "Best of" Collection Editors' Picks For Authors Information for Authors Author Services Best of: Author Profiles Submit Alerts Table of Contents Editors' Picks OnlineFirst Citation Author/Keyword My Alert Summary & Preferences News Cancer Discovery News COVID-19 Search More Search for this keyword Advanced Search AACR Publications Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Clinical Cancer Research Molecular Cancer Research Molecular Cancer Therapeutics User menu Register Log in My Cart Search Search for this keyword Advanced search Home About The Journal AACR Journals Subscriptions Permissions and Reprints Reviewing Articles OnlineFirst Current Issue Past Issues Meeting Abstracts Cancer Immunology Essentials Collections COVID-19 & Cancer Resource Center "Best of" Collection Editors' Picks For Authors Information for Authors Author Services Best of: Author Profiles Submit Alerts Table of Contents Editors' Picks OnlineFirst Citation Author/Keyword My Alert Summary & Preferences News Cancer Discovery News COVID-19 Search More Search for this keyword Advanced Search The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff. Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available . Cancer Immunology at the Crossroads: Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy Read the November issue! About the cover: Chen et al. find that tumor-derived IL33, whose expression increases after ICB treatment, and ST2 signaling in nontumor cells are key to inducing antitumor responses. Find out more in the aricle. Artwork by Lewis Long. Cancer Immunology at the Crossroads Read: Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy, Anthony B. Rodriguez, et al. Editorial Read: Building on Success, from Editors-in-Chief Robert D. Schreiber and Philip D. Greenberg. 1 2 3 From the Current Issue What We're Reading A Sampling of Highlights from the Literature Cancer Immunol Res November 1 2020 8 (11) 1335-1335; Cancer Immunology Miniatures Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas Jarem Edwards , Peter M. Ferguson , Serigne N. Lo , Inês Pires da Silva , Andrew J. Colebatch , Hansol Lee , Robyn P.M. Saw , John F. Thompson , Alexander M. Menzies , Georgina V. Long , Felicity Newell , John V. Pearson , Nicola Waddell , Nicholas K. Hayward , Peter A. Johansson , Graham J. Mann , Richard A. Scolyer , Umaimainthan Palendira and James S. Wilmott Cancer Immunol Res November 1 2020 8 (11) 1346-1353; DOI:10.1158/2326-6066.CIR-19-0835 Analysis shows that TMB does not correlate with tumor immune infiltrates, including tumor-resident CD8 + T cells, in acral, mucosal, and cutaneous melanomas. The data indicate that TMB is not a significant driver of antitumor responses. Priority Brief A DNA-Launched Nanoparticle Vaccine Elicits CD8 + T-cell Immunity to Promote In Vivo Tumor Control Ziyang Xu , Neethu Chokkalingam , Edgar Tello-Ruiz , Megan C. Wise , Mamadou A. Bah , Susanne Walker , Nicholas J. Tursi , Paul D. Fisher , Katherine Schultheis , Kate E. Broderick , Laurent Humeau , Daniel W. Kulp and David B. Weiner Cancer Immunol Res November 1 2020 8 (11) 1354-1364; DOI:10.1158/2326-6066.CIR-20-0061 DNA nanoparticle vaccination plus electroporation robustly induces CD8 + CTL responses that are able to control, or protect from, melanoma growth in mice. The data demonstrate the utility of this platform and offer a strategy to boost antitumor responses. OnlineFirst Articles MM Treatment with dCAR138-38–Redirected T Cells Anat Globerson Levin , et al. Antitumor Activity Triggered by an Anti-ICOS Antibody Richard C.A. Sainson , et al. Integrated Immune-Molecular Profiling in Endometrial Cancer Nanda Horeweg , et al. TGFβ1 Regulates PD-1 mRNA to Impair Antitumor Activity Pengfei Wu , et al. Load more Advertisement -- -- Back to top Home Alerts Feedback Privacy Policy Facebook Twitter LinkedIn YouTube RSS Articles Online First Current Issue Past Issues Cancer Immunology Essentials Info for Authors Subscribers Advertisers Librarians Reviewers About Cancer Immunology Research About the Journal Editorial Board Permissions Submit a Manuscript Copyright © 2020 by the American Association for Cancer Research. Cancer Immunology Research eISSN: 2326-6074 ISSN: 2326-6066 Advertisement...